Editas Medicine Inc (EDIT)
4.655
-0.10
(-2.00%)
USD |
NASDAQ |
Jun 28, 14:46
Editas Medicine Research and Development Expense (Annual): 177.65M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 177.65M |
| December 31, 2022 | 174.96M |
| December 31, 2021 | 142.51M |
| December 31, 2020 | 158.00M |
| December 31, 2019 | 96.90M |
| Date | Value |
|---|---|
| December 31, 2018 | 90.65M |
| December 31, 2017 | 83.16M |
| December 31, 2016 | 56.98M |
| December 31, 2015 | 18.85M |
| December 31, 2014 | 5.073M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
96.90M
Minimum
2019
177.65M
Maximum
2023
150.00M
Average
158.00M
Median
2020
Research and Development Expense (Annual) Benchmarks
| Vertex Pharmaceuticals Inc | 3.163B |
| Bristol-Myers Squibb Co | 9.299B |
| Regeneron Pharmaceuticals Inc | 4.439B |
| Cabaletta Bio Inc | 55.42M |
| Oragenics Inc | 15.49M |